← Back to Search

Endovascular Device

Nellix System for Abdominal Aortic Aneurysm (EVAS IDE Trial)

N/A
Waitlist Available
Led By Jeffrey Carpenter, MD
Research Sponsored by Endologix
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post-procedure to 5 years
Awards & highlights

EVAS IDE Trial Summary

This trial is testing a new device to treat abdominal aortic aneurysms. The goal is to see if it is safe and effective.

Eligible Conditions
  • Abdominal Aortic Aneurysm

EVAS IDE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~post-procedure to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and post-procedure to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Major Adverse Events at 30 Days
Treatment Success at 1 Year
Secondary outcome measures
Adverse Events
Aneurysm Rupture
Clinical Utility Outcomes
+8 more

EVAS IDE Trial Design

1Treatment groups
Experimental Treatment
Group I: Nellix SystemExperimental Treatment1 Intervention
Nellix Endovascular Aneurysm Sealing System is the only arm for this study. This is a single arm study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nellix System
2013
N/A
~340

Find a Location

Who is running the clinical trial?

EndologixLead Sponsor
22 Previous Clinical Trials
3,639 Total Patients Enrolled
Jeffrey Carpenter, MDPrincipal InvestigatorCooper Hospital, Camden, NJ
1 Previous Clinical Trials
98 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~29 spots leftby Apr 2025